| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| comparative study | Q58901591 |
| P50 | author | Umberto Veronesi | Q780378 |
| Jack Cuzick | Q21005493 | ||
| Andrea LaCroix | Q28360453 | ||
| Ivana Sestak | Q42801190 | ||
| Mitch Dowsett | Q53099690 | ||
| P2093 | author name string | Bernardo Bonanni | |
| Andrea DeCensi | |||
| Victor Vogel | |||
| Steve Cummings | |||
| John F Forbes | |||
| Joseph P Costantino | |||
| D Lawrence Wickerham | |||
| Bruce H Mitlak | |||
| Trevor Powles | |||
| Leslie Ford | |||
| John Mershon | |||
| SERM Chemoprevention of Breast Cancer Overview Group | |||
| P2860 | cites work | Mammographic Density and the Risk and Detection of Breast Cancer | Q59545042 |
| Tamoxifen and contralateral breast cancer | Q69867231 | ||
| Chemoprevention of breast cancer with selective oestrogen-receptor modulators | Q79448439 | ||
| Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial | Q79803594 | ||
| The Combination of Estimates from Different Experiments | Q100745541 | ||
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial | Q28244429 | ||
| Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women | Q28251695 | ||
| Lasofoxifene in postmenopausal women with osteoporosis | Q28274186 | ||
| Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial | Q28277066 | ||
| Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study | Q28281843 | ||
| Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial | Q28289262 | ||
| Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy | Q28300092 | ||
| Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q29619251 | ||
| Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). | Q30816691 | ||
| Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer | Q34110074 | ||
| Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation | Q34191632 | ||
| Overview of the main outcomes in breast-cancer prevention trials | Q35057371 | ||
| Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study | Q42540931 | ||
| Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. | Q42836293 | ||
| Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention | Q43761708 | ||
| First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial | Q44146948 | ||
| Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene | Q45168977 | ||
| Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women | Q46315785 | ||
| Exemestane for breast-cancer prevention in postmenopausal women. | Q48657440 | ||
| Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. | Q51182331 | ||
| P433 | issue | 9880 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| estrogen | Q277954 | ||
| meta-analysis | Q815382 | ||
| selective estrogen-receptor modulators | Q903917 | ||
| prevention | Q1717246 | ||
| anticarcinogens | Q4774590 | ||
| breast neoplasm | Q23929670 | ||
| P304 | page(s) | 1827-1834 | |
| P577 | publication date | 2013-04-30 | |
| 2013-05-25 | |||
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data | |
| P478 | volume | 381 |
| Q92685952 | A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model |
| Q90453820 | A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer |
| Q93103805 | A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density |
| Q40660629 | A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women. |
| Q40639052 | A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen |
| Q35116627 | A systematic in silico mining of the mechanistic implications and therapeutic potentials of estrogen receptor (ER)-α in breast cancer |
| Q92102602 | Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool |
| Q35322167 | Advances in the prevention of Alzheimer's disease and dementia |
| Q38375045 | Advances in the recognition and management of hereditary cancer |
| Q44659430 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial |
| Q57108351 | Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review |
| Q39315948 | Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting |
| Q28388192 | Association of lifestyle and demographic factors with estrogenic and glucocorticogenic activity in Mexican American women |
| Q30301033 | Atypical hyperplasia of the breast--risk assessment and management options |
| Q91989403 | Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report |
| Q35836307 | Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study |
| Q26774593 | Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake |
| Q61306878 | Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study |
| Q35812120 | Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ |
| Q28269986 | Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials |
| Q43624639 | Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen? |
| Q43536111 | Breast cancer prevention: SERMs come of age. |
| Q59789681 | CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study |
| Q35834376 | Can the breast screening appointment be used to provide risk assessment and prevention advice? |
| Q60938839 | Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? |
| Q38652183 | Cancer Prevention: Lessons Learned and Future Directions |
| Q64891209 | Cancer Progress and Priorities: Uterine Cancer. |
| Q28080472 | Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches |
| Q91823349 | Cancer prevention: Molecular and epidemiologic consensus |
| Q34604351 | Chemo/Dietary prevention of cancer: perspectives in China |
| Q60936278 | Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment |
| Q27000363 | Chemoprevention of cancer: current evidence and future prospects |
| Q36349610 | Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer |
| Q36825778 | Clinical pathology of metastatic gastric carcinoma to the breast: A report of two cases and a review of literature |
| Q35683807 | Clinical utility of exemestane in the treatment of breast cancer |
| Q34736112 | Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer |
| Q34994574 | Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing |
| Q37533025 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer |
| Q33599463 | Current strategies for the prevention of breast cancer |
| Q51837751 | Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study. |
| Q37720955 | Decision making for breast cancer prevention among women at elevated risk |
| Q93111830 | Diagnostic terminology used to describe atypia on breast core needle biopsy: correlation with excision and upgrade rates |
| Q50083416 | Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention. |
| Q35179983 | Effect of tamoxifen and raloxifene on the proliferative activity of the breast epithelium in premenopausal women. |
| Q91811507 | Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review |
| Q30380010 | Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence |
| Q38753738 | Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations |
| Q47424270 | Endometrial cancer evolution: new molecular-biologic types and hormonal-metabolic shifts |
| Q91989178 | Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast |
| Q38792320 | Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications. |
| Q26773464 | Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis |
| Q38659935 | Genetic screening for gynecological cancer: where are we heading? |
| Q47884776 | Genetic testing in women with breast cancer: implications for treatment |
| Q59504056 | Germline oncopharmacogenetics, a promising field in cancer therapy |
| Q86253807 | IBIS-I tamoxifen update: maturity brings questions |
| Q49412994 | Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms. |
| Q93107774 | Immunomodulation of carcinogens-induced steroids-dependent human diseases |
| Q52571636 | Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis. |
| Q38778524 | Incorporating Biomarkers in Studies of Chemoprevention |
| Q90011399 | Isolation, purification and characterization of naturally derived Crocetin beta-d-glucosyl ester from Crocus sativus L. against breast cancer and its binding chemistry with ER-alpha/HDAC2 |
| Q96302976 | Key steps for effective breast cancer prevention |
| Q100389129 | Local transdermal delivery of telapristone acetate through breast skin, compared to oral treatment: a randomized double-blind, placebo-controlled Phase II trial |
| Q53280631 | Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation. |
| Q88282837 | Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density |
| Q94397749 | Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review |
| Q28086915 | Medical prevention of breast cancer |
| Q26797207 | Molecular cancer prevention: Current status and future directions |
| Q41696217 | Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review |
| Q60946525 | Mutations and Breast Cancer Prevention |
| Q47666739 | NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction |
| Q38152315 | New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use. |
| Q33698278 | Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer |
| Q35892049 | Novel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers Study |
| Q39026644 | Obesity and Breast Cancer |
| Q30936399 | Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction |
| Q30277966 | Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. |
| Q35072474 | Overdiagnosis in breast cancer chemoprevention trials |
| Q38702563 | Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). |
| Q58609596 | Population Based Testing for Primary Prevention: A Systematic Review |
| Q92281922 | Potential Mechanisms of Age Acceleration Caused by Estrogen Deprivation: Do Endocrine Therapies Carry the Same Risks? |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q33658005 | Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue |
| Q33722922 | Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes |
| Q34393592 | Preventative therapies for healthy women at high risk of breast cancer |
| Q51843372 | Preventing invasive breast cancer using endocrine therapy. |
| Q87307255 | Prevention: targeted therapy-anastrozole prevents breast cancer |
| Q38651770 | Preventive therapy for cancer |
| Q35744037 | Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? |
| Q59349295 | Progress in preventive therapy for cancer: a reminiscence and personal viewpoint |
| Q36320380 | Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture. |
| Q51272824 | Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice. |
| Q38825454 | Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women |
| Q93025306 | Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia |
| Q90186243 | Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil |
| Q37524981 | Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies |
| Q64101959 | Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study |
| Q42372951 | Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. |
| Q33632008 | Reproductive risk factors and breast cancer subtypes: a review of the literature |
| Q47100005 | Risk Factors and Preventions of Breast Cancer |
| Q26991921 | Risk determination and prevention of breast cancer |
| Q34974865 | Risk-benefit profiles of women using tamoxifen for chemoprevention |
| Q24185817 | Risk-reducing medication for primary breast cancer: a network meta-analysis |
| Q91590902 | Risk-reducing medications for primary breast cancer: a network meta-analysis |
| Q38677822 | Safety issues and adverse reactions with osteoporosis management |
| Q87047613 | Sequential use of antiresorptives in younger women |
| Q35207952 | Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors |
| Q47551685 | Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). |
| Q57172011 | Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health |
| Q38150222 | Suitable trial designs and cohorts for preventive breast cancer agents |
| Q42629638 | Supporting families with Cancer: A patient centred survivorship model of care |
| Q64246321 | T-type Calcium Channels in Cancer |
| Q38987813 | TRPM8 promotes aggressiveness of breast cancer cells by regulating EMT via activating AKT/GSK-3β pathway |
| Q44328480 | Tamoxifen Use Correlates with Increased Risk of the First Episode of Ischemic Cerebrovascular Disease in Older Women with Breast Cancer: A Case-Control Study in Taiwan |
| Q88125155 | Tamoxifen and ERα36: Fertilizing the seeds of breast cancer metastasis |
| Q36634556 | Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial |
| Q38827549 | Tamoxifen in men: a review of adverse events |
| Q45003739 | Targeted therapies: Any surprises from selective oestrogen-receptor modulators? |
| Q35564703 | Targeting thyroid hormone receptor beta in triple-negative breast cancer |
| Q33814691 | The burden of breast cancer from China to Italy |
| Q26822900 | The failure of cancer chemoprevention |
| Q51748246 | The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. |
| Q38703578 | The selective estrogen receptor modulators in breast cancer prevention |
| Q64120581 | Therapeutic cancer prevention: achievements and ongoing challenges - a focus on breast and colorectal cancer |
| Q33888331 | Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model |
| Q52801719 | Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews. |
| Q37681706 | Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. |
| Q91989928 | Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial |
| Q36452292 | Women's Expectations for Breast Cancer Prevention and Early Detection: High Expectations Can Be Achieved |
| Q35661551 | Women's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique |
| Q38164994 | bHLH-PAS proteins in cancer |
Search more.